Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
6.52
-0.34 (-4.96%)
Jul 10, 2026, 4:00 PM EDT - Market closed
Gyre Therapeutics Employees
Gyre Therapeutics had 625 employees as of December 31, 2025. The number of employees increased by 46 or 7.94% compared to the previous year.
Employees
625
Change (1Y)
46
Growth (1Y)
7.94%
Revenue / Employee
$187,278
Profits / Employee
-$10,179
Market Cap
726.91M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 625 | 46 | 7.94% |
| Dec 31, 2024 | 579 | -14 | -2.36% |
| Dec 31, 2023 | 593 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 371 |
| Omeros | 175 |
| Allogene Therapeutics | 152 |
| Prime Medicine | 146 |
| Aura Biosciences | 113 |
| Aclaris Therapeutics | 73 |
| SpyGlass Pharma | 68 |
| Candel Therapeutics | 55 |
GYRE News
- 19 days ago - Gyre Therapeutics Registration statement: Registration filing - Filings
- 19 days ago - Gyre Therapeutics files to sell 30.22M shares of common stock for holders - TheFly
- 4 weeks ago - Gyre Therapeutics Transcript: AGM 2026 - Transcripts
- 5 weeks ago - Gyre Therapeutics Slides: Corporate presentation - Filings
- 6 weeks ago - Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm - Newsfile Corp
- 2 months ago - Gyre Therapeutics announces China NMPA acceptance of F351 NDA - TheFly
- 2 months ago - Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment - GlobeNewsWire
- 2 months ago - Gyre Therapeutics reports Q1 EPS (10c) vs. 0c last year - TheFly